...
首页> 外文期刊>Clinical ophthalmology >532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy
【24h】

532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy

机译:532-NM亚阈值微型激光器用于治疗慢性中央浆液性视网膜病变

获取原文
           

摘要

Introduction: Subthreshold micropulse laser treatment with a 532 nm (532-SML) wavelength has been suggested as a treatment option for the treatment of chronic central serous retinopathy (cCSR). The objective is to present its effects and complications. Methods: We present a retrospective cohort study of cCSR patients submitted to 532-SML. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) parameters – central macular thickness, subfoveal outer nuclear layer, external limiting membrane, ellipsoid band, interdigitation band, subretinal fluid and choroidal thickness – were evaluated before and 12 weeks after treatment. A power of 50%, a duty?cycle of 5%, exposure time of 200 ms and a spot size of 160 μm were the applied laser parameters. Results: We included 26 eyes. Overall there were no significant changes in visual acuity (median 0.20 (IQR 0) logMAR before and after treatment) or SD-OCT parameters. However, visual benefits occurred in 42.3% (n=11) of the?patients and in half of the cases, subretinal fluid was completely reabsorbed. There were no complications. Conclusion: In?this?study, 532-SML was overall ineffective on cCSR as it did not lead to significant changes in the overall median visual acuity and SD-OCT parameters. However, some patients may have benefited functionally and anatomically from the treatment; further investigation is necessary to understand the potential of 532-SML.
机译:介绍:具有532nm(532-Sml)波长的亚阈值微型激光处理已被提出作为治疗慢性中央浆浆视网膜病变(CCSR)的治疗选择。目的是呈现其影响和并发症。方法:我们提出了提交至532-SML的CCSR患者的回顾性队列研究。最佳校正的视力(BCVA)和光谱域光学相干断层扫描(SD-OCT)参数 - 中央黄斑厚度,子卵形外核层,外部限制膜,椭圆形频带,分区,分子流体和脉络膜厚度 - 以前评价治疗后12周。功率为50%,占空比5%,暴露时间为200ms,光斑尺寸为160μm。结果:我们包括26只眼睛。总体而言,视敏度没有显着变化(治疗前后的中位数0.20(IQR 0)Logmar)或SD-OCT参数。然而,在42.3%(n = 11)中发生的视觉益处在?患者的一半和一半的情况下,亚阈液完全重新吸收。没有并发症。结论:在?这个研究中,532-SML对CCSR的总体无效,因为它不会导致整体中位视力和SD-OCT参数的显着变化。然而,一些患者可能从治疗中使用功能和解剖学造成的;需要进一步调查以了解532-SML的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号